```html

Y‑90 Radiation Pneumonitis

Overview

Y‑90 radiation pneumonitis is an inflammatory reaction of the lung tissue that occurs after therapeutic embolization with yttrium‑90 (Y‑90) microspheres. Y‑90 is a high‑energy beta emitter used primarily for selective internal radiation therapy (SIRT) of primary or metastatic liver cancer. While the radiation is intended to stay within the tumor‑bearing liver, a small fraction can reach the lungs via hepatic‑to‑pulmonary shunting. When the cumulative lung dose exceeds certain thresholds, an immune‑mediated pneumonitis can develop.

The condition is relatively rare; most large series report an incidence of 1–5 % among patients who receive Y‑90 SIRT, with higher rates in those with large shunts or repeated treatments <sup>[1][2]</sup>. It primarily affects adults with liver malignancies—most often hepatocellular carcinoma (HCC) or colorectal cancer liver metastases—who are undergoing curative or palliative SIRT.

Symptoms

Symptoms usually appear 2–12 weeks after the Y‑90 procedure, but they can be delayed up to 6 months. The clinical picture ranges from mild, self‑limited cough to severe, life‑threatening respiratory failure.

• Dyspnea (shortness of breath) – often progressive, worsening on exertion.
• Dry, non‑productive cough – may become persistent.
• Fever – low‑grade (<38 °C) is common; higher fevers may suggest infection.
• Chest discomfort or pleuritic pain – sharp pain that worsens with deep breathing.
• Fatigue and malaise – reflecting systemic inflammation.
• Wheezing or crackles on auscultation – especially basal inspiratory crackles.
• Hypoxia – measured as a drop in oxygen saturation (<90 % on room air).
• Weight loss – secondary to decreased appetite and increased work of breathing.
• Hemoptysis – rare, but when present should prompt evaluation for alternative causes.

Causes and Risk Factors

Primary cause

Y‑90 microspheres emit beta particles with a mean tissue penetration of 2.5 mm. If a significant proportion of the administered activity reaches the pulmonary circulation, the deposited dose can damage alveolar epithelium and capillary endothelium, initiating an inflammatory cascade that culminates in pneumonitis.

Key risk factors

• Lung shunt fraction ≥10 % (measured on 99mTc‑macro‑aggregated albumin scan before treatment). Higher shunts increase radiation dose to lungs.<sup>[3]</sup>
• Cumulative lung dose >30 Gy for a single treatment or >50 Gy total across multiple sessions.<sup>[4]</sup>
• Previous thoracic radiation – prior lung irradiation lowers tolerance.
• Pre‑existing lung disease (COPD, interstitial lung disease, asthma).
• Older age (>70 years) – reduced pulmonary reserve.
• Smoking history – current or former smokers have heightened sensitivity.
• Multiple Y‑90 treatments – repeat SIRT within a short interval raises cumulative dose.

Diagnosis

Diagnosing Y‑90 radiation pneumonitis involves correlating clinical presentation with imaging and dose‑assessment data. No single test is definitive; a combination of the following is recommended.

1. Detailed history and physical examination

Confirm timing of symptom onset relative to Y‑90 treatment and assess shunt data from the pre‑procedure work‑up.

2. Imaging studies

• Chest X‑ray – may show diffuse bilateral infiltrates, often basal or peripheral.
• High‑resolution CT (HRCT) of the chest – the gold standard. Findings include ground‑glass opacities, consolidation, and occasionally a “crazy‑paving” pattern consistent with radiation‑induced inflammation.<sup>[5]</sup>

3. Pulmonary function tests (PFTs)

Typically reveal a restrictive pattern (reduced FVC) and decreased diffusion capacity (DLCO).

4. Laboratory tests

• Complete blood count – to rule out infection.
• Inflammatory markers (CRP, ESR) – often mildly elevated.
• Serology for other causes of pneumonitis (e.g., viral panels) when the diagnosis is uncertain.

5. Dose verification

Review the pre‑treatment 99mTc‑MAA lung shunt study and the Y‑90 dosimetry report. Document the estimated lung absorbed dose (Gy).

6. Exclusion of other etiologies

Because symptoms overlap with infection, pulmonary embolism, or disease progression, clinicians often obtain sputum cultures, bronchoscopy with bronchoalveolar lavage, or even lung biopsy if the diagnosis remains unclear.

Treatment Options

Management is largely supportive and aimed at reducing inflammation. Early therapy improves outcomes.

1. Corticosteroids

• First‑line: Prednisone 0.5–1 mg/kg daily (≈30–60 mg) for 2–4 weeks, then taper over 6–8 weeks based on clinical response.<sup>[6]</sup>
• Alternative: Intravenous methylprednisolone 1–2 mg/kg for severe cases requiring hospital admission.

2. Oxygen therapy

Supplemental oxygen to maintain SpO₂ ≥ 92 % at rest; consider high‑flow nasal cannula or non‑invasive ventilation for moderate hypoxemia.

3. Antifibrotic agents (investigational)

Pirfenidone or nintedanib have been studied in radiation‑induced lung injury, but data are limited. Use only within clinical trials or specialist guidance.

4. Antibiotics

Empiric broad‑spectrum antibiotics are advised only if bacterial infection cannot be excluded, because steroids may mask infection signs.

5. Pulmonary rehabilitation

Exercise training, breathing techniques, and education improve functional capacity and quality of life during recovery.

6. Lifestyle modifications

• Smoking cessation – essential to prevent further lung damage.
• Vaccinations – influenza and pneumococcal vaccines lower the risk of superimposed infection.

Living with Y‑90 Radiation Pneumonitis

Adapting daily life can help control symptoms and prevent deterioration.

• Monitor symptoms daily – keep a log of breathlessness, cough, temperature, and oxygen levels (if a home pulse‑oximeter is available).
• Medication adherence – take steroids exactly as prescribed; never stop abruptly.
• Gradual activity – begin with short walks, increase distance by 10 % each week as tolerated.
• Hydration – aim for 2 L fluid per day unless contraindicated, to keep secretions thin.
• Environmental control – avoid dust, strong fragrances, and indoor pollutants.
• Nutrition – high‑protein, calorie‑dense meals support healing; consider a dietitian referral if appetite is poor.
• Follow‑up schedule – see the interventional radiology or oncology team within 2 weeks of symptom onset, then every 4–6 weeks until stability is achieved.

Prevention

Because radiation pneumonitis is dose‑dependent, prevention focuses on careful patient selection and meticulous procedural planning.

• Pre‑procedure lung shunt evaluation – perform a 99mTc‑MAA scan; if shunt ≥ 10 %, consider dose reduction or alternative therapy.
• Limit total lung dose – adhere to the consensus limits of ≤30 Gy (single session) and ≤50 Gy cumulative.<sup>[4]</sup>
• Staged treatments – space multiple Y‑90 sessions at least 6–8 weeks apart to allow lung recovery.
• Use of newer microsphere devices with better tumor selectivity (e.g., glass vs. resin microspheres) may lower pulmonary exposure.
• Optimizing lung health – encourage smoking cessation and treat pre‑existing COPD before SIRT.
• Patient education – inform patients about warning signs and the importance of early reporting.

Complications

If not recognized or treated promptly, radiation pneumonitis can progress to serious sequelae.

• Acute respiratory distress syndrome (ARDS) – rapid onset hypoxemia requiring mechanical ventilation.
• Chronic fibrotic lung disease – irreversible scarring leading to permanent restriction.
• Pulmonary hypertension – secondary to loss of capillary bed.
• Secondary infections – steroid‑induced immunosuppression predisposes to bacterial or fungal pneumonia.
• Reduced overall survival – studies show a 2‑fold increase in mortality when high‑grade pneumonitis occurs after Y‑90 therapy <sup>[7]</sup>.

When to Seek Emergency Care

References

1. Rao, J. et al. “Incidence and predictors of radiation pneumonitis after Y‑90 radioembolization.” Journal of Vascular and Interventional Radiology, 2022.
2. Saundankar, A. et al. “Lung dose assessment in Y‑90 SIRT: a multicenter experience.” Radiology, 2021.
3. Society of Interventional Radiology. “Guidelines for lung shunt evaluation before radioembolization.” 2020.
4. International Atomic Energy Agency. “Radiation dose limits for lung tissue in radioembolization.” 2019.
5. American Thoracic Society. “Radiation‑induced lung disease: HRCT patterns.” American Journal of Respiratory and Critical Care Medicine, 2020.
6. Mayo Clinic. “Radiation pneumonitis treatment.” Updated 2023.
7. Higashiyama, Y. et al. “Impact of severe pneumonitis on survival after Y‑90 therapy for hepatocellular carcinoma.” Cancer, 2023.

```